We're happy to announce that CRO Simbec-Orion and biotx.ai launch strategic partnership to de-risk early-stage drug development with AI supported clinical trial design. https://lnkd.in/eeNVWsV5
biotx.ai
Informationsdienste
Potsdam, Brandenburg 2.178 Follower:innen
Unlocking the full therapeutic potential of the human genome through algorithms
Info
biotx.ai delivers predictive biomarkers as a basis for decision support in precision medicine. We use novel, state of the art, machine learning approaches specifically designed to find complex patterns in biomedical data.
- Website
-
http://www.biotx.ai
Externer Link zu biotx.ai
- Branche
- Informationsdienste
- Größe
- 2–10 Beschäftigte
- Hauptsitz
- Potsdam, Brandenburg
- Art
- Privatunternehmen
- Gegründet
- 2017
- Spezialgebiete
- machine learning, artificial intelligence, biomedicine, next generation biomarkers, diagnostics und biomarkerdiscovery
Orte
-
Primär
Am Mühlenberg 11
Potsdam, Brandenburg 14476, DE
Beschäftigte von biotx.ai
-
Hussein Kanji
Early stage venture capitalist
-
Bernhard Schmidt
Obsessed with Finding and Turning Innovation into Reality in Healthcare I New Business Development I Venture Development I Venture Clienting | Coach…
-
Marco Schmidt
Chief Scientific Officer - biotx.ai
-
Justin Cope
Data Scientist, Software Developer
Updates
-
Reflecting on 2023
🌟 Reflecting on 2023 🌟 As we approach the end of 2023, I find myself immensely proud to have engaged in profound discussions with over 250 biotech executives throughout the year. Amidst these conversations, a recurring challenge emerged—one that unites these innovative companies: the pressing issue of the reproducibility of academic results. Sadly, this isn't a new dilemma. A study by Prinz et al from Bayer in 2011 revealed that 65% of published data on drug targets lacks reproducibility: https://lnkd.in/ehnZQPRB This year, I witnessed firsthand the repercussions of this challenge, particularly for biotechs. Phase II studies faltered, and upon analysis, it became evident that foundational academic work was flawed. A biotech company facing a failed Phase II trial encounters the ultimate nightmare, often delivering a devastating blow that can lead to its demise. So, what's the solution? We need to #democratize the validation of academic results. It should be feasible to independently, swiftly, and cost-effectively validate academic results on a drug target. Excitingly, at biotx.ai, we're paving the way for just that. We will worker harder in 2024 to offer independent, fast, and cost-effective validation of any drug target using causal models based on large population biobank data. I'm thrilled to share that our collaboration with Simbec-Orion, a full-service CRO, is a significant stride towards early validation and improved study design. The synergy is promising, and I look forward to the impact we can collectively make. As the year draws to a close, I want to express my gratitude to our partners, customers, and the entire biotx.ai community. Here's to a Merry Christmas, a Happy New Year, and a future filled with impactful collaborations. Warm regards, Marco 🚀🎄✨